Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TetraFluvac TF Vaccine in Healthy Thais
NCT05895955Phase 2Completed
- Sponsor
- Mahidol University
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TetraFluvac TF in influenza (2 arms), sponsored by Mahidol University. Primary endpoints: Number and percentage of Solicited local adverse events post-vaccination at day 7, Number and percentage of Solicited systemic adverse events post-vaccination at day 7 and 4 more. Started Nov 2023; status: completed.
02
Drugs
TetraFluvac TF
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05895955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895955.